Insmed is a biopharmaceutical company based in Bridgewater, New Jersey, focusing on therapies for rare diseases, employing 912 staff. Its key products include ARIKAYCE, brensocatib, and TPIP for various lung diseases.
Sara Bonstein sold 58,400 shares of INSM on 21 July at $103.03 per share, worth a total of $6.0M. They now own 99,815 INSM shares, or a 44% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
